mitoxantrone has been researched along with Cardiomyopathy, Hypertrophic in 1 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okamoto, M | 1 |
| Miyazaki, H | 1 |
| Tsuzuki, M | 1 |
| Ino, T | 1 |
| Ezaki, K | 1 |
| Hirano, M | 1 |
1 other study available for mitoxantrone and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
[Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy].
Topics: Aclarubicin; Adrenergic beta-Antagonists; Adult; Antibiotics, Antineoplastic; Cardiomyopathy, Hypert | 1995 |